Rapalogix Health

About Rapalogix Health

Rapalogix Health is a biotechnology company founded in 2023 and headquartered in New York, developing solutions to enhance skin health by focusing on cellular longevity. The company was co-founded by Rahul Mehta, PhD, who serves as CEO, James Peyer, PhD (CEO of Cambrian Bio), Brent L. Saunders (CEO of Bausch & Lomb), and Doris Day, MD, a board-certified dermatologist. Dr. Mehta brings over 35 years of experience in pharmaceutical research and development, including a previous role as Vice President of Research and Development at AbbVie where he led the SkinMedica® team. The founding team's expertise in longevity science, dermatology, and pharmaceutical commercialization drives the company's mission to address the root biological causes of skin aging. The company's core technology centers on modulating the mTOR (mechanistic target of rapamycin) pathway, a master regulator of cell metabolism and longevity. Specifically, their approach targets the TORC1 complex, which can become overactive with age, disrupting a cell's ability to repair itself. By inhibiting TORC1, Rapalogix aims to reset cells to a healthier state, restoring their natural capacity for repair and renewal, a process that improves long-term skin health rather than just addressing surface symptoms. This approach is designed to make other aesthetic treatments and skincare products work more effectively. In May 2026, Rapalogix Health launched its first product, the Re-Q Pro-Longevity Face Serum. The serum features the proprietary, patent-pending molecule RLX-201, a specific TORC-1 inhibitor described as a 'rapalog' (analog of rapamycin). This active ingredient is designed to provide the longevity benefits of rapamycin without the associated side effects. The product is sold through dermatology offices and is positioned as a new category in professional skincare, creating a "longevity stack" for physicians to offer patients. Clinical studies have shown that the serum improves skin firmness, radiance, and texture. In January 2026, the company won 'Start-Up of the Year' at the IMCAS Innovation Tank in Paris, a competitive showcase for emerging technologies in dermatology and aging science. The company raised $9.1M in a Seed Round in June 2025, with investors including Quiet Capital and The Ax Incubator. Keywords: skin longevity, cellular aging, mTOR pathway, TORC1 inhibitor, regenerative dermatology, RLX-201, Re-Q Pro-Longevity Serum, rapalog, fibroblast technology, aesthetic medicine, cosmetic dermatology, Cambrian Bio spinout, skin healthspan, cellular repair, anti-aging biotechnology, professional skincare, topical rapamycin analog, molecular skincare